CALC · CalciMedica, Inc.
CalciMedica Inc (CALC)
What's happening
- CALC is up 10.85% today, trading at $1.18. — Live quote
- It's trading within 3% of its 52-week low ($1.00). (Finnhub fundamentals)
- Volume today (2,210) is well below its 3-month average of 210,390. (Finnhub fundamentals)
- Reports earnings on 2026-11-10, 19 days away. (Finnhub earnings calendar)
- Last quarter's EPS missed estimates: $-2.25 actual vs. $-1.45 estimated (-54.8%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Aggregate ratings for 2026-10-01 (9 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
Earnings Trends (Quarterly EPS Actual vs Estimate)
Valuation Measures & Ratios
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $83.2M | $44.8M | $235.6M | $118.4M | $130.3M |
| P/E | -5.06 | -3.24 | -9.65 | -5.75 | -8.99 |
| Price/Book | 15.09 | -40.58 | -879.18 | 19.40 | 11.96 |
| ROE | -298.13% | 1252.36% | 9111.94% | -337.05% | -133.03% |
| ROA | -84.27% | -160.60% | -163.75% | -107.81% | -57.14% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 8-K, filed 2026-10-16; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Trailing 52-week price return is -92.7%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on CALC
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Operating income | -$4.0M | -$5.6M | -$5.6M | -$6.6M | -$6.5M | -$5.7M | -$6.5M | -$5.8M |
| Net income | -$7.7M | $5.0M | -$7.8M | -$6.0M | -$5.0M | -$5.6M | -$4.0M | $130.0K |
| EPS (diluted) | $-0.45 | $0.30 | $-0.52 | $-0.40 | $-0.36 | $-0.50 | $-0.36 | $0.01 |
| EPS (basic) | $-0.45 | $0.31 | $-0.52 | $-0.40 | $-0.36 | $-0.50 | $-0.36 | $0.01 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $19.5M | $8.6M | $13.6M | $14.9M | $19.1M | $25.3M | $19.8M | $16.2M |
| Total liabilities | $14.0M | $9.7M | $20.2M | $15.2M | $13.0M | $14.5M | $5.4M | $7.2M |
| Stockholders' equity | $5.5M | -$1.1M | -$6.6M | -$268.0K | $6.1M | $10.9M | $14.4M | $9.0M |
| Total current assets | $19.5M | $8.6M | $13.5M | $14.9M | $19.0M | $25.2M | $19.7M | $15.7M |
| Total current liabilities | $3.5M | $5.3M | $3.8M | $3.7M | $3.5M | $4.5M | $3.7M | $3.8M |
| Cash & equivalents | $18.6M | $8.2M | $11.5M | $5.5M | $5.9M | $12.6M | $7.9M | $9.2M |
| Marketable securities (current) | $0 | $0 | $1.5M | $8.6M | $12.0M | $12.1M | $10.7M | $5.5M |
| Other current assets | — | — | — | — | — | — | — | — |
| Marketable securities (non-current) | — | — | — | — | — | — | — | — |
| Property, plant & equipment | $36.0K | $43.0K | $50.0K | $49.0K | $105.0K | $118.0K | $119.0K | $130.0K |
| Accounts payable | $2.1M | $1.7M | $1.2M | $1.1M | $1.9M | $2.0M | $2.0M | $1.5M |
| Accrued liabilities | — | — | — | — | — | — | — | — |
| Other current liabilities | — | — | — | — | — | — | — | — |
| Common stock & paid-in capital | $6.0K | $4.0K | $4.0K | $4.0K | $4.0K | $4.0K | $4.0K | $3.0K |
| Retained earnings | -$192.0M | -$184.3M | -$189.3M | -$178.6M | -$170.8M | -$164.8M | -$159.8M | -$155.5M |
| Accumulated other comprehensive income (loss) | -$1.0K | — | $0 | $1.0K | -$4.0K | -$1.0K | $4.0K | $4.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$4.6M | -$4.9M | -$4.9M | -$4.8M | -$6.7M | -$4.9M | -$5.0M | -$4.7M |
| Investing cash flow | $42.0K | $1.5M | $7.1M | $3.5M | $134.0K | -$1.2M | -$5.2M | $8.7M |
| Financing cash flow | $15.0M | $0 | $3.8M | $818.0K | -$102.0K | $10.7M | $8.9M | $16.0K |
| Free cash flow | -$4.6M | -$4.9M | -$4.9M | -$4.8M | -$6.7M | -$4.9M | -$5.0M | -$4.7M |
| Capital expenditures | $0 | $0 | $6.0K | $8.0K | $5.0K | $9.0K | $2.0K | $6.0K |
| Depreciation & amortization | — | — | — | — | — | — | — | — |
| Share-based compensation | $540.0K | $561.0K | $622.0K | $625.0K | $1.2M | $549.0K | $632.0K | $781.0K |
| Change in accounts payable | -$627.0K | $514.0K | $44.0K | -$796.0K | -$1.0K | -$87.0K | $484.0K | -$609.0K |
| Purchases of investments | $0 | $0 | $496.0K | $1.5M | $7.3M | $6.6M | $10.2M | $984.0K |
| Tax withholding on stock comp | — | — | — | — | — | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating income | -$23.1M | -$24.2M | -$38.1M | -$14.2M | -$35.9M |
| Net income | -$29.6M | -$13.7M | -$34.4M | -$7.8M | -$35.8M |
| EPS (diluted) | $-1.97 | $-1.22 | $-7.66 | $-111.16 | $-1.69 |
| EPS (basic) | $-1.97 | $-1.22 | $-7.66 | $-111.16 | $-1.69 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $13.6M | $19.8M | $12.2M | $3.3M | $69.1M |
| Total liabilities | $20.2M | $5.4M | $4.0M | $12.6M | $4.1M |
| Stockholders' equity | -$6.6M | $14.4M | $8.2M | -$71.3M | -$64.0M |
| Total current assets | $13.5M | $19.7M | $11.6M | $1.7M | $67.1M |
| Total current liabilities | $3.8M | $3.7M | $4.0M | $4.8M | $4.1M |
| Cash & equivalents | $11.5M | $7.9M | $5.5M | $1.3M | $13.4M |
| Marketable securities (current) | $1.5M | $10.7M | $5.7M | $0 | $50.3M |
| Other current assets | — | — | — | — | $1.4M |
| Property, plant & equipment | $50.0K | $119.0K | $167.0K | $147.0K | $2.0M |
| Accounts payable | $1.2M | $2.0M | $1.4M | $2.9M | $527.0K |
| Accrued liabilities | — | — | — | $200.0K | $304.0K |
| Other current liabilities | — | — | $0 | $199.0K | $3.2M |
| Common stock & paid-in capital | $4.0K | $4.0K | $1.0K | $1.0K | $2.0K |
| Retained earnings | -$189.3M | -$159.8M | -$146.1M | -$111.7M | -$169.2M |
| Accumulated other comprehensive income (loss) | $0 | $4.0K | $2.0K | -$37.0K | -$16.0K |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$21.2M | -$21.1M | -$25.7M | -$11.8M | -$31.5M |
| Investing cash flow | $9.6M | -$4.4M | $8.9M | -$4.0K | $10.8M |
| Financing cash flow | $15.2M | $28.0M | $20.9M | $8.5M | $695.0K |
| Free cash flow | -$21.2M | -$21.2M | -$25.8M | -$11.8M | -$32.0M |
| Capital expenditures | $28.0K | $8.0K | $78.0K | $4.0K | $488.0K |
| Depreciation & amortization | — | — | $58.0K | $52.0K | — |
| Share-based compensation | $3.0M | $2.3M | $12.0M | $1.8M | $5.4M |
| Change in accounts payable | -$840.0K | $601.0K | -$1.4M | $933.0K | -$2.1M |
| Purchases of investments | $15.9M | $29.0M | $6.1M | $35.6M | $94.6M |
| Tax withholding on stock comp | — | — | — | $139.0K | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding CALC as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2026-06-25 to 2026-06-25
Recent transactions
- Insiders have net bought 248,972 shares over the last 182 days, across 1 purchase and 0 sales.
- Most recent: Middleton Fred A (Reporting person) — Open market purchase of 248,972 shares on 2026-06-25.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Middleton Fred A | Reporting person | Open market purchase | 2026-06-25 | 248,972 |
| Hebbar Sudarshan | Chief Medical Officer | Grant / award | 2026-06-25 | 124,486 |
| WILSON ROBERT N | Reporting person | Grant / award | 2026-06-25 | 1,182,621 |
| Roberts Eric W | CHIEF BUSINESS OFFICER | Grant / award | 2026-06-25 | 186,729 |
| Leheny A. Rachel | CHIEF EXECUTIVE OFFICER | Grant / award | 2026-06-25 | 186,729 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-06-25 | Middleton Fred A | Reporting person | Open market purchase | 248,972 | $0.80 |
| 2026-06-25 | Hebbar Sudarshan | Chief Medical Officer | Grant / award | 124,486 | $0.80 |
| 2026-06-25 | WILSON ROBERT N | Reporting person | Grant / award | 1,182,621 | $0.80 |
| 2026-06-25 | Roberts Eric W | CHIEF BUSINESS OFFICER | Grant / award | 186,729 | $0.80 |
| 2026-06-25 | Leheny A. Rachel | CHIEF EXECUTIVE OFFICER | Grant / award | 186,729 | $0.80 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 08:20 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-16 | 8-K | 2026-10-15 | View on SEC.gov → |
| 2026-10-05 | 4 | 2026-10-01 | View on SEC.gov → |
| 2026-10-05 | 4 | 2026-10-01 | View on SEC.gov → |
| 2026-10-05 | 4 | 2026-10-01 | View on SEC.gov → |
| 2026-10-05 | 4 | 2026-10-01 | View on SEC.gov → |
| 2026-10-05 | 4 | 2026-10-01 | View on SEC.gov → |
| 2026-09-30 | 8-K | 2026-09-30 | View on SEC.gov → |
| 2026-09-28 | 4 | 2026-09-24 | View on SEC.gov → |
| 2026-09-28 | 4 | 2026-09-24 | View on SEC.gov → |
| 2026-09-28 | 4 | 2026-09-24 | View on SEC.gov → |
| 2026-09-28 | 4 | 2026-09-24 | View on SEC.gov → |
| 2026-09-16 | 8-K | 2026-09-15 | View on SEC.gov → |
Recent news
Headlines about CALC (CalciMedica, Inc.). Links open the publisher — we don’t host full articles.
-
Prosus stock: Fair Value Calculator values Prosus stock at EUR 51.70
AD HOC NEWS · 2026-10-21 -
Griffith Foods Launches Nutrient Density Calculator, a Scientific Tool To Help Food Manufacturers Navigate the Next Era of Nutrition
Yahoo Finance · 2026-10-21 -
5paisa Unveils Dual Calculator Tools to Assist Mutual Fund Planning
Yahoo Finance · 2026-10-21 -
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 2026-10-21 -
Dividend Growth Rate: What is It, Calculation, Applications, Importance, Risks, Benefits & More
Investing.com · 2026-10-20 -
Another professional opportunity prompts the CFO of CalciMedica (CALC) to give resignation notice.
Stock Titan · 2026-10-16 -
Calcimedica, Inc. Announces Resignation of Stephen Bardin as Chief Financial Officer, Effective October 15, 2026
www.marketscreener.com · 2026-10-16 -
Calcimedica, Inc. Announces Resignation of Stephen Bardin as Principal Accounting Officer and Principal Financial Officer, Effective October 15, 2026
www.marketscreener.com · 2026-10-16
No headlines in this category right now — try “All”.